Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Foreign Offices Are Only The Start To Improving Import Safety – Experts

This article was originally published in The Tan Sheet

Executive Summary

FDA needs the cooperation of foreign governments to improve import safety, but still could be overwhelmed by rapidly expanding industry overseas and a lack of resources, according to food and drug industry stakeholders

You may also be interested in...



China Takes "Baby Steps" Toward More Open Supplement Regulation

China's health product regulators are taking "baby steps" toward more streamlined approval of supplements, but multi-ingredient products likely will face a series of hurdles before market, says Jeff Crowther, former executive director of the Natural Products Association's Beijing office

China Takes "Baby Steps" Toward More Open Supplement Regulation

China's health product regulators are taking "baby steps" toward more streamlined approval of supplements, but multi-ingredient products likely will face a series of hurdles before market, says Jeff Crowther, former executive director of the Natural Products Association's Beijing office

China Takes "Baby Steps" Toward More Open Supplement Regulation

China's health product regulators are taking "baby steps" toward more streamlined approval of supplements, but multi-ingredient products likely will face a series of hurdles before market, says Jeff Crowther, former executive director of the Natural Products Association's Beijing office

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102378

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel